Compass Ion Advisors’s AstraZeneca AZN Stock Holding History

Compass Ion Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$219K	Buy	+1,110	New	+$214K	0.02%	262
2024 Q4	–	Sell	-1,365	Closed	-$213K	–	260
2024 Q3	$213K	Sell	1,365 -317	-19%	-$51.2K	0.03%	248
2024 Q2	$228K	Hold	1,682	–	–	0.03%	213
2024 Q1	$228K	Sell	1,682 -118	-7%	-$15.6K	0.03%	213
2023 Q4	$242K	Sell	1,800 -430	-19%	-$55.9K	0.04%	206
2023 Q3	$302K	Buy	+2,230	New	+$305K	0.05%	182

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Compass Ion Advisors's AZN Position: Q1 2026 in Review

Compass Ion Advisors opened a new position in AstraZeneca (AZN) in Q1 2026: 1,110 shares worth $219K. The stake represents 0.02% of the portfolio and ranks #262 among its holdings. This is a return to the name: Compass Ion Advisors previously reported a position in AZN as recently as Q3 2024.

Compass Ion Advisors first reported a position in AZN in Q3 2023 and has held it in 6 quarters since. The position peaked at $302K in Q3 2023. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Compass Ion Advisors held 1,110 shares of AstraZeneca worth $219K as of Q1 2026.
AstraZeneca was a new Compass Ion Advisors position in Q1 2026.
AstraZeneca made up 0.02% of Compass Ion Advisors's portfolio in Q1 2026, its #262 holding.
Compass Ion Advisors first reported a position in AstraZeneca in Q3 2023 and has held it in 6 quarters since.
Compass Ion Advisors's AstraZeneca position peaked at $302K in Q3 2023.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Compass Ion Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.